Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer
Clinical Summary:
- Design/Context: The single-arm, phase 2 SATEEN trial evaluated sacituzumab govitecan plus trastuzumab in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
- Key Outcomes: The trial demonstrated minimal response and short progression-free survival, leading to early study closure.
- Clinical Relevance: These findings suggest limited benefit of sequential topoisomerase I antibody drug conjugates in this setting and highlight the need for optimized sequencing strategies in HER2-positive breast cancer.
Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab among heavily pretreated patients with HER2-positive metastatic breast cancer.
Results demonstrated that this combination showed limited activity after prior trastuzumab deruxtecan (T-DXd), providing important insight into antibody-drug conjugate sequencing in this setting.
Dr Tarantino presented these results at the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Congress in Berlin, Germany.
Source:
Tarantino P. Efficacy and safety of sacituzumab govitecan (SG) plus trastuzumab in patients with HER2+ metastatic breast cancer after prior trastuzumab deruxtecan (T-DXd): Results from the phase II SATEEN trial. Presented at European Society for Medical Oncology (ESMO) Breast Cancer Congress; March 6 - 8, 2026; Berlin, Germany. LBA4.
